Conexeu Sciences Appoints Life Sciences Veteran Daniel M. Bradbury as Chairman of the Board of Directors
Key Highlights
- ➤Daniel M. Bradbury appointed Conexeu (CNXU) board chairman effective December 1, 2026
- ➤Jeff Sharpe steps down as chairman and director to make way for Bradbury
- ➤Conexeu plans first-quarter 2027 510(k) submission for its initial indication
- ➤Bradbury previously led Amylin through acquisition by Bristol-Myers Squibb valued approximately $7 billion
Expert Statements
Miles Harrison, President and Chief Executive Officer of Conexeu
“On behalf of the Board and the entire Conexeu team, I want to thank Jeff for his leadership and commitment. He guided Conexeu through its Nasdaq listing and helped build the foundation we stand on today.”
Miles Harrison, President and Chief Executive Officer of Conexeu
“We are delighted to welcome Dan as Chairman. He has led a company from development through regulatory approval, commercial launch and a major acquisition, and has chaired the boards of public and private life sciences companies for more than a decade. His experience will be invaluable as we prepare for our planned 510(k) submission and the commercial steps that follow.”
Daniel M. Bradbury, Chairman of the Board of Directors of Conexeu Sciences
“Conexeu has built a regenerative tissue platform with broad potential in areas of high unmet need.”
Daniel M. Bradbury, Chairman of the Board of Directors of Conexeu Sciences
“I am pleased to join the Board as Chairman at an important point in the Company's development. I look forward to working with Miles, the Board, and the management team as Conexeu moves toward its first regulatory submission and commercial entry. I also thank Jeff for his service and for the strong position in which he leaves the Board.”
RENO, Nev., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a preclinical-stage regenerative tissue platform company, today announced the appointment of Daniel M. Bradbury as Chairman of the Board of Directors, effective December 1, 2026. Mr. Bradbury succeeds Jeff Sharpe, who has stepped down as Chairman and Director of the Company to specifically make way for Mr. Bradbury.
Mr. Bradbury brings more than 40 years of experience creating and carrying out strategies that transform businesses, bring novel medicines to market, and build shareholder value. He served as President and Chief Executive Officer of Amylin Pharmaceuticals, Inc. from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012, in a transaction valued at approximately $7 billion. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-weekly therapy to treat diabetes, and was listed on the Nasdaq 100. Before joining Amylin, he spent ten years in marketing and sales roles at SmithKline Beecham Pharmaceuticals.
Get started
Create a free account to read the full story.
